1579151-60-2

Upstream product

• 130273-48-2 (3R,4S,5S)-clausenamidone 
• 108-24-7 acetic anhydride 

Downstream Products

• 595582-27-7 (+)-(3R,4S,5S,6R)-3-O-acetylclausenamide 
• 722525-94-2 (-)-(3R,4S)-3-O-acetyl-Δ^5,6clausenamide 
• 722526-00-3 (-)-(3R,4S)-Δ^5,6clausenamide 
• 722526-12-7 (±)-(3R,4R,5S,6R)-5-hydroxyclausenamide 
• 722526-06-9 (-)-(3R,4R,5R,6S)-5-hydroxyclausenamide 
• 722526-17-2 (+)-(3R,4R,5R,6S)-3-O-acetyl-5-hydroxyclausenamide 
• 1579151-64-6 (+)-(3R,4R,5S,6R)-3-O-acetyl-5-hydroxyclausenamide 
• 722526-30-9 (+)-(3R,4R,5R)-3-O-acetyl-5-hydroxyclausenamidone 
• 722526-35-4 (+)-(3R,4R,5R,6R)-3-O-acetyl-5-hydroxyclausenamide 
• 595582-28-8 (±)-(3R,4R,5R,6R)-5-hydroxyclausenamide 

Relevant academic research and scientific papers

Optical-activity neoclausenamidone derivative and application thereof

The invention discloses an optical-activity neoclausenamidone derivative and application thereof. The structural formula of a compound is shown in the description (I), wherein R is C1-C4 paraffin, C2-C4 alkylene and C2-C4 alkyne or -COR1; R1 is selected f

Studies on the synthesis and biological evaluation of the metabolite of clausenamide CM2 and its stereoisomers

The synthesis and biological evaluation of 5-hydroxy clausenamide (CM 2), one of the major metabolites of clausenamide, and its stereoisomers have been carried out. The absolute configurations of (-)- and (+)-CM2 were assigned as 3S,